0 484

Cited 12 times in

Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction

DC Field Value Language
dc.contributor.author고영국-
dc.contributor.author권혁문-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author남정모-
dc.contributor.author신동호-
dc.contributor.author안철민-
dc.contributor.author이승준-
dc.contributor.author장양수-
dc.contributor.author조덕규-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍범기-
dc.contributor.author홍성진-
dc.date.accessioned2021-04-29T17:14:59Z-
dc.date.available2021-04-29T17:14:59Z-
dc.date.issued2021-02-
dc.identifier.issn1936-8798-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182247-
dc.description.abstractObjectives: The aim of this study was to assess whether the effects of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) are consistent among patients presenting with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction, and unstable angina treated with drug-eluting stents. Background: Ticagrelor monotherapy after short-term DAPT has not been investigated in patients with STEMI. Methods: This was a pre-specified, stratified, subgroup analysis of the STEMI cohort from the TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome) trial, which constituted 36% of the total population. The primary outcome was a composite of major bleeding and major adverse cardiac and cerebrovascular events (MACCE; death, myocardial infarction, stent thrombosis, stroke, or target vessel revascularization). The secondary outcomes were major bleeding and MACCE. Results: The incidence of the primary outcome was 4.4% in patients with STEMI (n = 1,103), 6.0% in those with non-ST-segment elevation myocardial infarction (n = 1,027), and 4.1% in those with unstable angina (n = 926), without statistical significance (p = 0.09). Compared with ticagrelor-based 12-month DAPT, ticagrelor monotherapy after 3-month DAPT showed consistent effects on the primary outcome across clinical presentations (p for interaction [pint] = 0.64). Furthermore, the effect of ticagrelor monotherapy on the reduction of major bleeding was consistent across clinical presentations (pint = 0.36). The effect of ticagrelor monotherapy on MACCE was also consistent in patients with STEMI, without evidence of a higher risk for MACCE (pint = 0.14). Conclusions: This pre-specified subgroup analysis revealed no heterogeneity in the effects of ticagrelor monotherapy after 3-month DAPT, compared with 12-month DAPT, for the primary outcome, major bleeding, and MACCE across clinical presentations including STEMI, though larger studies are needed to demonstrate these findings with adequate power. (Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome [TICO Study]; NCT02494895).-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfJACC-CARDIOVASCULAR INTERVENTIONS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleTicagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeung-Jun Lee-
dc.contributor.googleauthorJae Young Cho-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorKyeong Ho Yun-
dc.contributor.googleauthorYongsung Suh-
dc.contributor.googleauthorYun-Hyeong Cho-
dc.contributor.googleauthorYong Hoon Kim-
dc.contributor.googleauthorAe-Young Her-
dc.contributor.googleauthorSungsoo Cho-
dc.contributor.googleauthorDong Woon Jeon-
dc.contributor.googleauthorSang-Yong Yoo-
dc.contributor.googleauthorDeok-Kyu Cho-
dc.contributor.googleauthorBum-Kee Hong-
dc.contributor.googleauthorHyuck Moon Kwon-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorChung-Mo Nam-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1016/j.jcin.2020.11.036-
dc.contributor.localIdA00127-
dc.contributor.localIdA00260-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA01264-
dc.contributor.localIdA02097-
dc.contributor.localIdA02269-
dc.contributor.localIdA02927-
dc.contributor.localIdA03448-
dc.contributor.localIdA03813-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04394-
dc.contributor.localIdA04403-
dc.relation.journalcodeJ01193-
dc.identifier.eissn1876-7605-
dc.identifier.pmid33602439-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1936879820323694-
dc.subject.keywordST-segment elevation myocardial infarction-
dc.subject.keyworddrug-eluting stent(s)-
dc.subject.keyworddual-antiplatelet therapy-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor권혁문-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor남정모-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor이승준-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor조덕규-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍범기-
dc.contributor.affiliatedAuthor홍성진-
dc.citation.volume14-
dc.citation.number4-
dc.citation.startPage431-
dc.citation.endPage440-
dc.identifier.bibliographicCitationJACC-CARDIOVASCULAR INTERVENTIONS, Vol.14(4) : 431-440, 2021-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.